Study of Epratuzumab in Systemic Lupus Erythematosus

Stopped early · Phase 3

Conditions studied: Systemic Lupus Erythematosus

In brief

The purpose of the study is to evaluate the safety \& efficacy of Epratuzumab with standard treatments for patients with SLE.

Key facts

Study ID

NCT00111306

Run by

UCB Pharma

People needed

510

Starts

2005-06-01

Expected to finish

2007-03-01

Last updated by the study team

2011-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has SLE by ACR revised criteria (meets <4 criteria);
• Has SLE with at least one elevated lupus antibody;
• Has new onset of severe lupus disease flare in at least one body or organ system, excluding renal or neurologic

You may not qualify if…

• Active severe CNS or Renal disease defined by BILAG as Level A
• Allergy to murine or human antibodies
• Antiphospholid antibodies AND a history of thrombocytopenic events

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Tucson, Arizona, United States
• Study site — Los Angeles, California, United States
• Study site — Upland, California, United States
• Study site — Denver, Colorado, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Baltimore, Maryland, United States
• Study site — New York, New York, United States
• Study site — The Bronx, New York, United States
• Study site — Durham, North Carolina, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Tulsa, Oklahoma, United States
• Study site — Charleston, South Carolina, United States
• Study site — Brussels, Belgium
• Study site — Debrecen, Hungary
• Study site — Amsterdam, Netherlands
• Study site — Santander, Spain
• Study site — Birmingham, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.